Catalyst
Slingshot members are tracking this event:
FDA Analysis Issued for Acadia's (ACAD) NUPLAZID (pimavanserin) in Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ACAD |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nuplazid, Parkinson's Disease Psychosis
